Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (248 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 30 Dec 2024 – 20 Aug 2026, limited by Bajaj Finserv Healthcare Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Bajaj Finserv Healthcare Fund | Nifty 500 |
|---|---|---|
| 30 Dec 2024 | ₹100.00 | ₹100.00 |
| 18 Feb 2025 | ₹88.30 | ₹92.19 |
| 09 Apr 2025 | ₹86.65 | ₹91.05 |
| 29 May 2025 | ₹93.40 | ₹102.26 |
| 17 Jul 2025 | ₹98.97 | ₹104.75 |
| 05 Sep 2025 | ₹97.17 | ₹102.11 |
| 25 Oct 2025 | ₹97.62 | ₹105.95 |
| 14 Dec 2025 | ₹96.48 | ₹106.12 |
| 02 Feb 2026 | ₹90.37 | ₹102.15 |
| 24 Mar 2026 | ₹90.46 | ₹94.23 |
| 12 May 2026 | ₹101.15 | ₹99.74 |
| 01 Jul 2026 | ₹107.39 | ₹103.37 |
| 20 Aug 2026 | ₹116.79 | ₹105.17 |
| Metric | Bajaj Finserv · Regular · IDCW NAV ₹11.77 Very High risk ★★★★★ 1Y | Category median Sectoral/ Thematic · 248 funds |
|---|---|---|
| +19.71% | +3.54% | |
| — | +11.47% | |
| — | +9.70% | |
| — | +10.32% | |
| +9.94% | +9.15% | |
| +25.65% | — | |
| — | +12.10% | |
| — | +10.32% | |
| — | +8.80% | |
| Risk | ||
| 13.48% | 15.91% | |
| 0.98 | 0.25 | |
| 1.32 | 0.32 | |
| -15.91% | -26.14% | |
| Nifty 500 | — | |
| — | -0.04% | |
| — | 0.98 | |
| — | 98.3% | |
| — | 101.5% | |
| 2.59% | 2.38% | |
| ₹329.96Cr | ₹1,160Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹500 | — | |
| 41% | 42% | |
| Siddharth Chaudhary | — | |
| 30 Dec 2024 | — | |
| 33 | — | |
| 58.4% | — | |
| 1.0% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.